Safety Study of FluMist With and Without Ampligen

2014-12-16 14:23:23 | BioPortfolio


The purpose of this study is to evaluate FluMist with and without Ampligen in healthy volunteers.


Influenza epidemics continue to represent a significant medical problem in the developed as well as the developing world. Even with existing vaccines, annual influenza epidemics typically results in 20-50 million cases, resulting in 30,000-40,000 deaths in the U.S. alone. A possible pandemic could have even more devastating consequences. Current vaccines have a number of disadvantages including slow and expensive manufacturing, and a relative lack of efficacy in elderly, children and immune-compromised populations. These disadvantages would be multiplied during a pandemic. Use of Ampligen® as an adjuvant combined with FluMist® has a number of potential advantages as compared to traditional inactivated vaccines: it is simpler to administer (intranasally), generation of a broader immunity at the natural site of entry of the influenza virus as well as systemic immunity (and hence should be more efficacious than traditional vaccines) and may stimulate cross-protection against pre-pandemic H5N1 and/or H7N9 avian influenza strains. As FluMist®, due to its intranasal administration, imitates the natural entry of the influenza virus, it will generate local 'first-line' immunity as well as the traditional systemic immunity; therefore, at least theoretically provide greater protection than injectable vaccines.

Study Design

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention


Influenza, Human


FluMist + Poly I:Poly C12U 50 ug, FluMist + Poly I:Poly C12U 200 ug, FluMist + Poly I:Poly C12U 500 ug, FluMist + Poly I:Poly C12U 1250 ug, FluMist + Placebo


The University of Alabama at Birmingham
United States




Hemispherx Biopharma

Results (where available)

View Results


Published on BioPortfolio: 2014-12-16T14:23:23-0500

Clinical Trials [242 Associated Clinical Trials listed on BioPortfolio]

Study of Ampligen in Chronic Fatigue Syndrome

This is an open label study of Ampligen in patients with chronic fatigue syndrome.

Phase I Oncovir Poly IC:LC and NY-ESO-1/gp100/MART

The purpose of this study is to determine what side effects CP 870,893 may cause when given with an immune stimulant called Oncovir poly IC:LC along with a melanoma vaccine. The CP 870,893...

Neoadjuvant Hiltonol® (PolyICLC) for Prostate Cancer

The purpose of this study is to test an approach of stimulating the body's immune system to attack prostate cancer. This study will test injection of a substance polylysine and carboxymeth...

Poly-ICLC in Treating Patients With Recurrent or Progressive Anaplastic Glioma

RATIONALE: Biological therapies such as poly-ICLC use different ways to stimulate the immune system and stop tumor cells from growing. PURPOSE: This phase II trial is studying how poly-IC...

A Trial of CDX-1401 in Combination With Poly-ICLC and Pembrolizumab, in Previously Treated Advanced Solid Tumor Patients

This study will look at the safety of the combination of three drugs (CDX-1401, Poly-ICL, and Pembrolizumab) and its effect on decreasing tumors. Pembrolizumab is an experimental cancer dr...

PubMed Articles [1545 Associated PubMed Articles listed on BioPortfolio]

Ruthenium(II) polypyridyl complex Ru(phen)dppz-idzo as a colorimetric molecular "light switch" and powerful stabilizer for the RNA triplex poly(U)·poly(A)*poly(U).

The interaction of [Ru(phen)dppz-idzo] (phen = 1,10-phenanthroline, dppz-idzo = dppz-imidazolone) with triplex RNA poly(U)·poly(A)*poly(U) was carried out by using spectroscopic and viscometr...

Syndioselective Polymerization of Vinylnaphthalene.

Coordination polymerizations of 1-vinylnaphthalene (1VN), 2-vinylnaphthalene (2VN) and 6-methoxy-2-vinylnaphthalene (MVN) are carried out at room temperature by using the half-sandwich scandium precur...

Synthesis of Y-Shaped OEGylated Poly(amino acid)s: The Impact of OEG Architecture.

OEGylation is an attractive approach to modifying poly(amino acid)s. OEG conjugation improves water-solubility of poly(amino acid)s, and confers possible thermal-responsive functionality for the conju...

Micellization of poly(2-vinylpyrridine)-b-poly(cyclohexyl methacrylate) (P2VP-b-PCHMA) block copolymers and their interpolymer complex formation in non-aqueous medium.

The interpolymer complex formation between poly(vinylpyridine)-based polymers with poly(acrylic acid) (PAA), in aqueous or organic medium, is driven by the hydrogen-bonding complexation. Well-defined ...

Extraction and quantification of polyphosphates in activated sludge from waste water treatment plants by P NMR spectroscopy.

Polyphosphate (poly-P) is a major constituent in activated sludge from wastewater treatment plants with enhanced biological phosphorus removal due to poly-P synthesis by poly-P accumulating organisms ...

Medical and Biotech [MESH] Definitions

A poly(A) binding protein that is involved in promoting the extension of the poly A tails of MRNA. The protein requires a minimum of ten ADENOSINE nucleotides in order for binding to mRNA. Once bound it works in conjunction with CLEAVAGE AND POLYADENYLATION SPECIFICITY FACTOR to stimulate the rate of poly A synthesis by POLY A POLYMERASE. Once poly-A tails reach around 250 nucleotides in length poly(A) binding protein II no longer stimulates POLYADENYLATION. Mutations within a GCG repeat region in the gene for poly(A) binding protein II have been shown to cause the disease MUSCULAR DYSTROPHY, OCULOPHARYNGEAL.

A poly(ADP-ribose) polymerase that contains two ZINC FINGERS in its N-terminal DNA-binding region. It modifies NUCLEAR PROTEINS involved in chromatin architecture and BASE EXCISION REPAIR with POLY ADENOSINE DIPHOSPHATE RIBOSE.

A poly(A) binding protein that has a variety of functions such as mRNA stabilization and protection of RNA from nuclease activity. Although poly(A) binding protein I is considered a major cytoplasmic RNA-binding protein it is also found in the CELL NUCLEUS and may be involved in transport of mRNP particles.

Post-translational modification of proteins with POLY ADENOSINE DIPHOSPHATE RIBOSE.

The addition of a tail of polyadenylic acid (POLY A) to the 3' end of mRNA (RNA, MESSENGER). Polyadenylation involves recognizing the processing site signal, (AAUAAA), and cleaving of the mRNA to create a 3' OH terminal end to which poly A polymerase (POLYNUCLEOTIDE ADENYLYLTRANSFERASE) adds 60-200 adenylate residues. The 3' end processing of some messenger RNAs, such as histone mRNA, is carried out by a different process that does not include the addition of poly A as described here.

More From BioPortfolio on "Safety Study of FluMist With and Without Ampligen"

Quick Search


Relevant Topics

Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...

Influenza or 'flu' is a respiratory illness associated with infection by influenza virus. Symptoms frequently include headache, fever, cough, sore throat, aching muscles and joints. There is a wide spectrum of severity of illness ranging from min...

Swine Flu - H1N1 influenza - H7N9
Swine flu is the common name given to a relatively new strain of influenza (flu) that caused a flu pandemic in 2009-2010. It is also referred to as H1N1 influenza (because it is the H1N1 strain of virus). The H1N1 flu virus will be one of the main vi...

Searches Linking to this Trial